• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Profound Medical Corp. - common stock (NQ:PROF)

    6.800 -0.010 (-0.15%)
    Streaming Delayed Price Updated: 1:23 PM EDT, Jul 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Profound Medical Corp. - common stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
    Company to explore the potential of integrating TULSA-PRO with PSMA PET molecular imaging technologies to enhance ablation planning and monitoring 
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical Reports Strong First Quarter 2026 Financial Results
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical Announces Upcoming Investor Events
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
    Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditions 
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
    Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systems 
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
    Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care 
    From Profound Medical Corp.
    Via GlobeNewswire
    InvestorNewsBreaks – Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) Closes $36 Million Registered Direct Offering
    Via Investor Brand Network
    News headline image
    Profound Medical Corp. Announces Closing of Private Placement
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical Corp. Announces Upsize of Private Placement
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
    Financing included participation by healthcare-dedicated investors alongside existing shareholders 
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
    Financing included participation by healthcare-dedicated investors alongside existing shareholders 
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical Reports Strong Third Quarter 2025 Financial Results
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Award for CAPTAIN Perioperative Data Presentation
    – CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target – 
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
    New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption 
    From Profound Medical Corp.
    Via GlobeNewswire
    News headline image
    Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease
    Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy 
    From Profound Medical Corp.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.